The conundrum of ALI and systemic embolic events: SEEing our way to improved vascular health

Vascular Medicine (United Kingdom)

Volumn 21, Issue 6, 2016, Pages 535-538

  Hirsch, Alan T ^a   Van'T Hof, Jeremy R ^a   Bonaca, Marc ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY OBSTRUCTION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIMB ISCHEMIA; LIMB SALVAGE; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SEX RATIO; THROMBOSIS; EMBOLISM;

EMBOLISM; HUMANS;

EID: 84999277873     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X16673730     Document Type: Review

References (10)

1. Creager MA, Kaufman JA, Conte MS,. Acute limb ischemia. N Engl J Med 2012; 366: 2198-2206.
2. Baril DT, Ghosh K, Rosen AB,. Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population. J Vasc Surg 2014; 60: 669-677.
3. Geller BJ, Giugliano RP, Braunwald E, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 trial. Am Heart J 2015; 170: 669-674.
4. Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67: 2719-2728.
5. Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: Results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients with Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation 2016; 133: 997-1005.
6. Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54. Eur Heart J 2016; 37: 1133-1142.
7. Bekwelem W, Adabag S, Duval S, et al. Extracranial systemic embolic events in patients with atrial fibrillation: Incidence, risk factors, and outcomes. Circulation 2015; 132: 796-803.
8. Duval S, Keo HH, Baumgartner I, et al., on behalf of the FRIENDS Investigators. The impact of prolonged lower limb ischemia on cardiovascular event rates, mortality and functional status: The FRIENDS Registry. Am Heart J 2014; 168: 577-587.
9. Landry G, Shukla R, Rahman A, et al. Demographic and echocardiographic predictors of anatomic site and outcomes of surgical interventions for cardiogenic limb emboli. Vasc Med 2016; 21: 528-534.
10. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease [lower extremity, renal, mesenteric, and abdominal aortic]). Circulation 2006; 113: e463-e654.